<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2127">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04419025</url>
  </required_header>
  <id_info>
    <org_study_id>CHA-IRB-1139/05/20</org_study_id>
    <nct_id>NCT04419025</nct_id>
  </id_info>
  <brief_title>Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease</brief_title>
  <official_title>Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge Health Alliance</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cambridge Health Alliance</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing
      those with mild or moderate COVID-19 from progressing to severe disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed of the study and potential risks and benefits, patients meeting
      eligibility requirements will be randomized to receive oral N-acetylcysteine (NAC) as
      follows:

      Inpatients:

        -  N-acetylcystine (NAC) 25 mg/kg PO (rounded up to the nearest 600 mg) q4hrs until
           discharge

        -  N-acetylcysteine (NAC) 1200 mg PO BID x 1 week post-discharge

      Outpatients:

      - N-acetylcysteine (NAC) 2400 mg PO x 1 then 1200 mg PO BID x 2 weeks
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to one of two groups in parallel for the duration of the study.
One arm is the intervention arm - those receiving N-acetylcysteine (NAC). One arm is the control group - those not receiving N-acetylcysteine (NAC).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in Respiratory Rate</measure>
    <time_frame>First hour after first dose of NAC</time_frame>
    <description>Decrease in dyspnea measured by respiratory rate (RR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital length of stay (LOS)</measure>
    <time_frame>Through study completion, average 9 months</time_frame>
    <description>Hospital LOS for admitted patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Need for mechanical ventilation</measure>
    <time_frame>Through study completion, average 9 months</time_frame>
    <description>Whether a patient needed mechanical ventilation (intubation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of time intubated</measure>
    <time_frame>Through study completion, average 9 months</time_frame>
    <description>If intubated, how long needing mechanical ventilation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Need for hospitalization</measure>
    <time_frame>Through study completion, average 9 months</time_frame>
    <description>Outpatients on NAC needing admission to the hospital</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recovery disposition</measure>
    <time_frame>Through study completion, average 9 months</time_frame>
    <description>Whether outpatients continued to recover as outpatients; whether admitted patients were managed on medical floors or level of care increased to ICU level of care; whether patients expired</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID</condition>
  <condition>Sars-CoV2</condition>
  <condition>SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>NAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving N-acetylcysteine (NAC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients not receiving N-acetylcysteine (NAC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>Oral formulation: 600 mg capsules of N-acetylcysteine</description>
    <arm_group_label>NAC</arm_group_label>
    <other_name>NAC, acetylcysteine, N-acetyl-L-cysteine, NALC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  known or suspect COVID-19 disease AND one or more of the following:

               -  Oxygen saturation as measured by pulse oximetry (SpO2) &lt;= 95% at rest on room air
                  (i.e. with no supplemental oxygen)

               -  Oxygen saturation as measured by pulse oximetry (SpO2) decreases to &lt;= 90% on
                  room air while walking (i.e. &quot;ambulatory desaturation&quot;)

               -  Respiratory Rate &gt;= 24 breaths per minute

               -  Fever defined as temperature &gt;= 100.1Â° Fahrenheit

               -  Radiographic evidence of pulmonary pathology consistent with COVID-19

               -  Use of acetaminophen (APAP, paracetamol) for symptom control

        Exclusion Criteria:

          -  Minors, pregnant women and people unable to provide informed consent are excluded from
             this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melisa Lai-Becker, MD</last_name>
    <phone>617-394-7424</phone>
    <email>melaibecker@cha.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Duncan Kuhn, MD</last_name>
    <email>dukuhn@cha.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHA Cambridge Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melisa Lai-Becker, MD</last_name>
      <email>melaibecker@cha.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Duncan Kuhn, MD</last_name>
      <email>dukuhn@cha.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rachel Hathaway, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alix Schrager, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHA Everett Hospital</name>
      <address>
        <city>Everett</city>
        <state>Massachusetts</state>
        <zip>02149</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melisa Lai-Becker, MD</last_name>
      <phone>617-394-7424</phone>
      <email>melaibecker@cha.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Duncan Kuhn, MD</last_name>
      <email>dukuhn@cha.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mary Regan, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHA Respiratory Clinic</name>
      <address>
        <city>Somerville</city>
        <state>Massachusetts</state>
        <zip>02143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lara Hall, MD</last_name>
      <email>lahall@cha.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Janice John, PA-C</last_name>
      <email>jnjohn@cha.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHA Somerville campus</name>
      <address>
        <city>Somerville</city>
        <state>Massachusetts</state>
        <zip>02144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melisa Lai-Becker, MD</last_name>
      <email>melaibecker@cha.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.NACinCOVID.info</url>
    <description>Website reviewing reasoning and references for using NAC as adjuvant therapy in treatment of COVID-19</description>
  </link>
  <link>
    <url>http://www.NACinCOVID.net</url>
    <description>Website reviewing reasoning and references for using NAC as adjuvant therapy in treatment of COVID-19</description>
  </link>
  <link>
    <url>http://www.NACinCOVID.org</url>
    <description>Website reviewing reasoning and references for using NAC as adjuvant therapy in treatment of COVID-19</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge Health Alliance</investigator_affiliation>
    <investigator_full_name>Melisa Lai-Becker</investigator_full_name>
    <investigator_title>Chief, CHA Everett Hospital Emergency Department; Director, CHA Division of Medical Toxicology</investigator_title>
  </responsible_party>
  <keyword>Glutathione</keyword>
  <keyword>Acetylcysteine</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>NAC</keyword>
  <keyword>COVID</keyword>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

